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S U M M A R Y
Non-tuberculous mycobacteria are rare but important causes of infection in HIV-positive individuals. A
28-year-old HIV-positive male presented with a high fever, non-productive cough, right subcostal pain,
splenomegaly, a very low CD4 count, elevated C-reactive protein and erythrocyte sedimentation rate,
and a normal white blood cell count. The suspicion of tuberculosis (TB) was very high, and sputum
samples were positive for acid-fast bacilli. Standard quadruple anti-TB therapy was initiated, but once
culture of the sample revealed Mycobacterium kansasii, pyrazinamide was withdrawn. Highly active
antiretroviral therapy (HAART) was initiated soon after, consisting of abacavir/lamivudine and efavirenz.
The patient’s general condition deteriorated 2 weeks after HAART initiation, which could have been due
to the development of immune reconstitution inﬂammatory syndrome (IRIS). The patient recovered and
was discharged in good condition. However, the results of resistance testing of the isolated organism
arrived after discharge, and showed isoniazid and streptomycin resistance. This is the ﬁrst case report of
M. kansasii infection from Serbia and shows the difﬁculties encountered during the course of treatment.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Mycobacterium kansasii belongs to the group of slowly-growing
non-tuberculous mycobacteria (NTM) and is an important cause of
infection in both HIV-positive and negative individuals.1 It is the
second most common cause of chronic pulmonary disease in HIV-
positive individuals, behind Mycobacterium avium.1,2 M. kansasii is
a ubiquitous organism. It is widespread in water and soil, and tap
water is the most common reservoir for this pathogen.1–3 Although
it is more frequently observed in immunocompromised individu-
als, an increasing incidence of this organism has not been observed
in the HIV/AIDS era.4 Prevalence rates vary among countries
worldwide,5 and in areas of high prevalence of Mycobacterium
tuberculosis, NTM are often unrecognized and underdiagnosed.4 In
Serbia, this pathogen is rarely mentioned, with very few papers* Corresponding author. Tel.: +381 60 6019358.
E-mail address: alexadespotovic@hotmail.com (A. Despotovic).
http://dx.doi.org/10.1016/j.ijid.2015.11.012
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).published regarding its identiﬁcation.6,7 This is the ﬁrst case report
from this country.
2. Case report
A 28-year old, HIV-positive male, with an illness that had
started 17 days prior to admission, presented at the outpatient
clinic with a high fever (up to 39.5 8C), accompanied by sweating,
pain in the left subcostal region, and a non-productive cough. He
also complained of generalized bone and joint pain.
On admission, the patient was subfebrile (37.4 8C), tachycardic
(heart rate 115/min), eupneic, had an oxygen saturation (SaO2) of
92%, and blood pressure of 125/70 mmHg. Physical examination
revealed oral candidiasis. No heart murmurs were observed, lung
sounds were clear, and neither hepatosplenomegaly nor abdomi-
nal pain was present. His personal history revealed that he had
been diagnosed with HIV 3 years ago, but since his CD4 cell count
had been repeatedly over 400/ml at diagnosis, highly active
antiretroviral therapy (HAART) had been deferred at that time.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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did not report recent travel and had not been in contact with
animals.
Once the patient was admitted, an extensive workup was
performed. Laboratory ﬁndings included a very low CD4 count (57/
ml) and elevated erythrocyte sedimentation rate (ESR; 90 mm/h),
C-reactive protein (CRP; 673 mg/L), and ﬁbrinogen (6.3 g/L), while
his leukocyte count was normal (7.8  109/l). Chest X-ray and
abdominal ultrasound had been performed 7 days before admis-
sion, revealing enhanced lung markings, a pronounced right hilus
with patchy adhesions of the diaphragmatic pleura, and spleno-
megaly (13.5  7.0 cm). A diagnostic panel including Venereal
Disease Research Laboratory (VDRL), Treponema pallidum hem-
agglutination assay (TPHA), hepatitis B virus surface antigen
(HBsAg), and hepatitis C virus antibodies (anti-HCV), as well as the
Mantoux tuberculin skin test, was negative.
Initial empirical therapy included trimethoprim–sulfamethox-
azole and ﬂuconazole to cover Pneumocystis jirovecii pneumonia
(PCP) and candidiasis, but due to his radiographic and clinical
ﬁndings, tuberculosis (TB) was also considered. Indeed, all three
sputum samples were positive for acid-fast bacilli. As a result,
standard quadruple anti-TB therapy was initiated. After 20 days of
therapy, the patient was afebrile and in good general condition, at
which point HAART was initiated, consisting of abacavir/lamivu-
dine and efavirenz. Two weeks after HAART initiation, his general
condition worsened; his fever spiked again (up to 40 8C), and a
chest X-ray revealed progression of the previous ﬁndings. HIV PCR
detected a viral load of 1270 copies of HIV RNA per milliliter of
plasma. The decline in his general condition, as well as the
progression of radiographic ﬁndings, are hallmarks of immune
reconstitution inﬂammatory syndrome (IRIS), which is observed in
patients initiating HAART with a low CD4 count. Mycobacterial
infections are often implicated in this phenomenon.8 However,
reports of IRIS with NTM are not common.8 Finally, sputum
cultures revealed M. kansasii. Since all strains are naturally
resistant to pyrazinamide, this drug was withdrawn from the
patient’s regimen.
The patient made a full recovery after 2 months of combined
therapy, and a total of six control sputum samples were negative.
He was discharged in good general condition and continued his
therapy as an outpatient. Ten days after discharge, however, the
results of microbial susceptibility testing were ﬁnalized and
delivered, showing resistance to isoniazid and streptomycin. For
technical reasons, it was not possible to perform a CD4+ count after
his discharge.
3. Discussion
M. kansasii is considered one of the most virulent NTM, and
observational studies have reported variable mortality rates.9,10
The clinical presentation is similar to that of M. tuberculosis,9–11
with symptoms of fever and cough usually lasting more than
30 days,10–14which is considerably longer than in our patient. After
initiation of HAART, the deterioration in his general condition
could have occurred for several reasons, one of them being
IRIS.14,15 IRIS is most commonly observed in HIV patients and is
considered to be a paradoxical reaction after the initiation of
HAART due to the restoration of immune function and ‘reactiva-
tion’ of the inﬂammatory response.8,15 It is initially characterized
by a worsening of the patient’s general condition and the
progression of chest X-ray ﬁndings, followed by a gradual
improvement in clinical and laboratory ﬁndings, which was the
case in the patient presented here.8,15
The initiation of HAART in patients with a mycobacterial co-
infection can be challenging, particularly in those with very low
CD4+ counts. However, it has been established that the earlyinitiation of therapy signiﬁcantly reduces mortality rates in
patients with CD4+ T-cell counts of <50/mm3, although there is
an increased risk of IRIS developing,24 as occurred in the present
case. For these reasons, HAART should be initiated early on and also
monitored closely.16,17
Isoniazid is a ﬁrst-line agent against M. kansasii, together with
rifampicin and ethambutol.18 However, resistance to isoniazid has
been reported,18 with in vitro resistance rates varying between 8%
and 25%.19–21 Taking into account that all isolates are naturally
resistant to pyrazinamide,18 there should be a concern regarding
future treatment, since resistance to other recommended agents
including rifampicin, clarithromycin, ciproﬂoxacin, and moxiﬂox-
acin has been reported as well, which could lead to the
development of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) strains.18–21 Current guidelines suggest that
M. kansasii in HIV-infected patients should be treated with
rifampicin, ethambutol, and either isoniazid or clarithromycin
for 15–18 months.17 Trimethoprim–sulfamethoxazole in high
doses is an alternative,18 but the present patient developed a
severe allergic reaction to this drug during his stay, and therefore
this was not considered as an option. The patient was switched to
clarithromycin and is now being followed up.
In conclusion, the resistance of M. kansasii to ﬁrst-line drugs, the
erratic clinical course, and the treatment limitations were the
challenges faced in this case. It is important to report cases of NTM
in the population, in order to obtain the real picture in terms of
prevalence of these rare strains, which can present a signiﬁcant
challenge in terms of treatment. Although the patient responded
well to therapy, some key principles have to be kept in mind.
Prompt implementation of all available diagnostic procedures is
vital, so that proper therapy can be given early on. Resistance of
mycobacterial organisms to both standard and non-standard anti-
TB agents is becoming an issue in medical practice, which is why
antimicrobial susceptibility testing is of vital importance. By doing
so, the development of multi-resistant strains can be delayed, and
the initiation and successful maintenance of HAART and anti-
mycobacterial therapy can be achieved.
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